NEW HOPE, Pa.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB: PRTX) announced today that it has unveiled pre-clinical data showing that PRTX-100, the company’s lead compound in development for various autoimmune disorders, inhibits the phagocytosis (ingestion) of platelets in vitro. The data from the study entitled, PRTX-100 Inhibits Platelet Phagocytosis In Vitro, were presented Saturday, December 9, 2006, by Chris Yatko, Research Scientist at Protalex, at the American Society of Hematology’s 48th Annual Meeting and Exposition in Orlando, Florida. Platelet phagocytosis is the effector limb of Idiopathic Thrombocytopenic Purpura (ITP), a rare blood-clotting disorder. As such, the results of the study indicate the potential of PRTX-100 for the treatment of patients with ITP.
